Encouraged by the activity observed with BAFF antibodies and the promising preliminary results of BAFF‐R CAR T treatment against B‐cell malignancies in the previous study, we have designed a series of experiments focusing on BAFF‐R CAR T therapy as a possible therapeutic approach for CLL patients. Here, TNFRSF13C is linked to B-cell chronic lymphocytic leukemia.